Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy.

Failing JJ, Dudek OA, Marin Acevedo JA, Chirila RM, Dong H, Markovic SN, Dronca RS.

Future Oncol. 2019 Aug;15(22):2645-2656. doi: 10.2217/fon-2019-0183. Epub 2019 Jul 12.

PMID:
31298573
2.

Immune Checkpoint Inhibitor Toxicities.

Marin-Acevedo JA, Chirila RM, Dronca RS.

Mayo Clin Proc. 2019 Jul;94(7):1321-1329. doi: 10.1016/j.mayocp.2019.03.012. Review.

PMID:
31272574
3.

Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?

Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN, Enninga EAL, Paludo J, Aguilera JV, Leventakos K, Lou Y, Kottschade LA, Dong H, Mansfield AS, Manochakian R, Adjei AA, Dronca RS.

Oncologist. 2019 Apr 29. pii: theoncologist.2019-0094. doi: 10.1634/theoncologist.2019-0094. [Epub ahead of print]

PMID:
31036771
4.

Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine.

Vera J, Paludo J, Kottschade L, Brandt J, Yan Y, Block M, McWilliams R, Dronca R, Loprinzi C, Grothey A, Markovic SN.

Support Care Cancer. 2019 Oct;27(10):3869-3875. doi: 10.1007/s00520-019-4654-2. Epub 2019 Feb 14.

PMID:
30767130
5.

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A.

Ann Oncol. 2019 Apr 1;30(4):582-588. doi: 10.1093/annonc/mdz011.

6.

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC.

Clin Cancer Res. 2018 Dec 1;24(23):6098. doi: 10.1158/1078-0432.CCR-18-3340. No abstract available.

PMID:
30510087
7.

Brachial Plexus Neuritis Associated With Anti-Programmed Cell Death-1 Antibodies: Report of 2 Cases.

Alhammad RM, Dronca RS, Kottschade LA, Turner HJ, Staff NP, Mauermann ML, Tracy JA, Klein CJ.

Mayo Clin Proc Innov Qual Outcomes. 2017 Sep 1;1(2):192-197. doi: 10.1016/j.mayocpiqo.2017.07.004. eCollection 2017 Sep.

8.

Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT.

Evans JD, Morris LK, Zhang H, Cao S, Liu X, Mara KC, Stish BJ, Davis BJ, Mansfield AS, Dronca RS, Iott MJ, Kwon ED, Foote RL, Olivier KR, Dong H, Park SS.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):229-240. doi: 10.1016/j.ijrobp.2018.09.001. Epub 2018 Sep 8.

PMID:
30205124
9.

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.

Yan Y, Kumar AB, Finnes H, Markovic SN, Park S, Dronca RS, Dong H.

Front Immunol. 2018 Jul 27;9:1739. doi: 10.3389/fimmu.2018.01739. eCollection 2018. Review.

10.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC.

Clin Cancer Res. 2018 Oct 15;24(20):4960-4967. doi: 10.1158/1078-0432.CCR-17-2386. Epub 2018 Apr 23. Erratum in: Clin Cancer Res. 2018 Dec 1;24(23):6098.

11.

CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.

Yan Y, Cao S, Liu X, Harrington SM, Bindeman WE, Adjei AA, Jang JS, Jen J, Li Y, Chanana P, Mansfield AS, Park SS, Markovic SN, Dronca RS, Dong H.

JCI Insight. 2018 Apr 19;3(8). pii: 97828. doi: 10.1172/jci.insight.97828. eCollection 2018 Apr 19.

12.

Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era.

Youland RS, Blanchard ML, Dronca R, Kottschade L, Markovic SN, Olivier KR, Park SS.

Clin Transl Radiat Oncol. 2017 Sep 30;6:25-30. doi: 10.1016/j.ctro.2017.09.002. eCollection 2017 Oct.

13.

Contraction of T cell richness in lung cancer brain metastases.

Mansfield AS, Ren H, Sutor S, Sarangi V, Nair A, Davila J, Elsbernd LR, Udell JB, Dronca RS, Park S, Markovic SN, Sun Z, Halling KC, Nevala WK, Aubry MC, Dong H, Jen J.

Sci Rep. 2018 Feb 1;8(1):2171. doi: 10.1038/s41598-018-20622-8.

14.

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS.

J Clin Oncol. 2018 Jun 10;36(17):1668-1674. doi: 10.1200/JCO.2017.75.6270. Epub 2017 Dec 28.

PMID:
29283791
15.

Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy.

Enninga EAL, Harrington SM, Creedon DJ, Ruano R, Markovic SN, Dong H, Dronca RS.

Am J Reprod Immunol. 2018 Feb;79(2). doi: 10.1111/aji.12795. Epub 2017 Dec 4.

16.

Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma.

Giridhar KV, Sosa CP, Hillman DW, Sanhueza C, Dalpiaz CL, Costello BA, Quevedo FJ, Pitot HC, Dronca RS, Ertz D, Cheville JC, Donkena KV, Kohli M.

Int J Mol Sci. 2017 Nov 3;18(11). pii: E2326. doi: 10.3390/ijms18112326.

17.

NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.

McWilliams RR, Allred JB, Slostad JA, Katipamula R, Dronca RS, Rumilla KM, Erickson LA, Bryce AH, Joseph RW, Kottschade LA, King DM, Leitch JM, Markovic SN.

Cancer. 2018 Feb 1;124(3):537-545. doi: 10.1002/cncr.31072. Epub 2017 Oct 17.

18.

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS.

J Immunother. 2017 Nov/Dec;40(9):334-340. doi: 10.1097/CJI.0000000000000186.

19.

Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors - a major reason for enhanced chemosensitivity?

Shenoy N, Dronca R, Quevedo F, Boorjian SA, Cheville J, Costello B, Kohli M, Witzig T, Pagliaro L.

Chin J Cancer Res. 2017 Aug;29(4):374-378. doi: 10.21147/j.issn.1000-9604.2017.04.11.

20.

Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011.

Enninga EAL, Moser JC, Weaver AL, Markovic SN, Brewer JD, Leontovich AA, Hieken TJ, Shuster L, Kottschade LA, Olariu A, Mansfield AS, Dronca RS.

Cancer Med. 2017 Oct;6(10):2203-2212. doi: 10.1002/cam4.1152. Epub 2017 Sep 6.

21.

18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma.

Youland RS, Packard AT, Blanchard MJ, Arnett AL, Wiseman GA, Kottschade LA, Dronca RS, Markovic SN, Olivier KR, Park SS.

Adv Radiat Oncol. 2017 Feb 24;2(2):204-210. doi: 10.1016/j.adro.2017.02.003. eCollection 2017 Apr-Jun.

22.

Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma.

Leon-Ferre RA, Kottschade LA, Block MS, McWilliams RR, Dronca RS, Creagan ET, Allred JB, Lowe VJ, Markovic SN.

Melanoma Res. 2017 Aug;27(4):335-341. doi: 10.1097/CMR.0000000000000344.

PMID:
28296712
23.

A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy.

Dong H, Yan Y, Dronca RS, Markovic SN.

SOJ Immunol. 2017;5(1):1-5. Epub 2017 Feb 25.

24.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O.

J Clin Oncol. 2016 Dec;34(34):4102-4109. Epub 2016 Oct 31.

25.

Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.

Leontovich AA, Dronca RS, Nevala WK, Thompson MA, Kottschade LA, Ivanov LV, Markovic SN; Melanoma Study Group of the Mayo Clinic Cancer Center.

Melanoma Res. 2017 Feb;27(1):32-42. doi: 10.1097/CMR.0000000000000290.

PMID:
27824739
26.

BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma.

Dronca RS, Mansfield AS, Park SS, Dong H.

Immunotherapy. 2016 Dec;8(12):1351-1353. doi: 10.2217/imt-2016-0100. Epub 2016 Oct 27. No abstract available.

27.

Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.

Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H.

Ann Oncol. 2016 Oct;27(10):1953-8. doi: 10.1093/annonc/mdw289. Epub 2016 Aug 8.

28.

T cell Bim levels reflect responses to anti-PD-1 cancer therapy.

Dronca RS, Liu X, Harrington SM, Chen L, Cao S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson MA, Mansfield AS, Park SS, Markovic SN, Dong H.

JCI Insight. 2016 May 5;1(6). pii: e86014.

29.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C.

JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059. Erratum in: JAMA. 2016 Jun 14;315(22):2472.

PMID:
27092830
30.

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD.

J Clin Oncol. 2016 May 1;34(13):1510-7. doi: 10.1200/JCO.2015.64.0391. Epub 2016 Mar 7.

31.

The use of pembrolizumab for the treatment of metastatic uveal melanoma.

Kottschade LA, McWilliams RR, Markovic SN, Block MS, Villasboas Bisneto J, Pham AQ, Esplin BL, Dronca RS.

Melanoma Res. 2016 Jun;26(3):300-3. doi: 10.1097/CMR.0000000000000242.

PMID:
26848796
32.

A gender factor in shaping T-cell immunity to melanoma.

Dronca RS, Dong H.

Front Oncol. 2015 Feb 2;5:8. doi: 10.3389/fonc.2015.00008. eCollection 2015. No abstract available.

33.

The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma.

Moser JC, Pulido JS, Dronca RS, McWilliams RR, Markovic SN, Mansfield AS.

Melanoma Res. 2015 Feb;25(1):59-63. doi: 10.1097/CMR.0000000000000125.

PMID:
25396683
34.

Immunomodulatory antibody therapy of cancer: the closer, the better.

Dronca RS, Dong H.

Clin Cancer Res. 2015 Mar 1;21(5):944-6. doi: 10.1158/1078-0432.CCR-14-2111. Epub 2014 Oct 28.

35.

Effect of β-adrenergic blockers and other antihypertensive drugs on the risk of melanoma recurrence and death--I.

Moser JC, Dronca RS, Markovic SN, Mansfield AS.

Mayo Clin Proc. 2014 Aug;89(8):1164-5. doi: 10.1016/j.mayocp.2014.06.001. No abstract available.

PMID:
25092366
36.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A.

Lancet. 2014 Sep 20;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2. Epub 2014 Jul 15.

PMID:
25034862
37.

Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.

Enninga EA, Holtan SG, Creedon DJ, Dronca RS, Nevala WK, Ognjanovic S, Markovic SN.

Mayo Clin Proc. 2014 Apr;89(4):520-35. doi: 10.1016/j.mayocp.2014.01.006. Review.

38.

Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.

Shah DJ, Dronca RS.

Mayo Clin Proc. 2014 Apr;89(4):504-19. doi: 10.1016/j.mayocp.2014.02.002. Review.

39.

NUT midline carcinoma: an aggressive intrathoracic neoplasm.

Parikh SA, French CA, Costello BA, Marks RS, Dronca RS, Nerby CL, Roden AC, Peddareddigari VG, Hilton J, Shapiro GI, Molina JR.

J Thorac Oncol. 2013 Oct;8(10):1335-8. doi: 10.1097/JTO.0b013e3182a00f41.

40.

Increasing incidence of melanoma among middle-aged adults: an epidemiologic study in Olmsted County, Minnesota.

Lowe GC, Saavedra A, Reed KB, Velazquez AI, Dronca RS, Markovic SN, Lohse CM, Brewer JD.

Mayo Clin Proc. 2014 Jan;89(1):52-9. doi: 10.1016/j.mayocp.2013.09.014.

41.

Cardiac Metastasis in Renal Cell Carcinoma without Vena Cava or Atrial Involvement: an Unusual Presentation of Metastatic Disease.

Zhang B, Malouf J, Young P, Kohli M, Dronca R.

Rare Tumors. 2013 Jul 5;5(3):e29. doi: 10.4081/rt.2013.e29. eCollection 2013.

42.

Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients.

Thompson RH, Boorjian SA, Kim SP, Cheville JC, Thapa P, Tarrel R, Dronca R, Costello B, Frank I.

BJU Int. 2014 May;113(5b):E17-21. doi: 10.1111/bju.12274. Epub 2013 Sep 5.

43.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A.

N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

44.

Rare presentations of primary melanoma and special populations: a systematic review.

Kottschade LA, Grotz TE, Dronca RS, Salomao DR, Pulido JS, Wasif N, Jakub JW, Bagaria SP, Kumar R, Kaur JS, Morita SY, Moran SL, Nguyen JT, Nguyen EC, Hand JL, Erickson LA, Brewer JD, Baum CL, Miller RC, Swanson DL, Lowe V, Markovic SN.

Am J Clin Oncol. 2014 Dec;37(6):635-41. doi: 10.1097/COC.0b013e3182868e82. Review.

45.

Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.

Zhang BY, Thompson RH, Lohse CM, Dronca RS, Cheville JC, Kwon ED, Leibovich BC.

BJU Int. 2013 Jun;111(7):1046-53. doi: 10.1111/bju.12075. Epub 2013 Apr 2.

46.

Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.

Dronca RS, Allred JB, Perez DG, Nevala WK, Lieser EA, Thompson M, Maples WJ, Creagan ET, Pockaj BA, Kaur JS, Moore TD, Marchello BT, Markovic SN.

Am J Clin Oncol. 2014 Aug;37(4):369-76. doi: 10.1097/COC.0b013e31827b45d4.

47.

Personalized therapy for metastatic melanoma: could timing be everything?

Dronca RS, Leontovich AA, Nevala WK, Markovic SN.

Future Oncol. 2012 Nov;8(11):1401-6. doi: 10.2217/fon.12.126. Review.

48.

Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes.

Mansfield AS, Nevala WK, Dronca RS, Leontovich AA, Shuster L, Markovic SN.

Clin Exp Immunol. 2012 Nov;170(2):186-93. doi: 10.1111/j.1365-2249.2012.04644.x.

49.

Melanoma brain metastases and vemurafenib: need for further investigation.

Rochet NM, Dronca RS, Kottschade LA, Chavan RN, Gorman B, Gilbertson JR, Markovic SN.

Mayo Clin Proc. 2012 Oct;87(10):976-81. doi: 10.1016/j.mayocp.2012.07.006.

50.

Fluctuation of systemic immunity in melanoma and implications for timing of therapy.

Leontovich AA, Dronca RS, Suman VJ, Ashdown ML, Nevala WK, Thompson MA, Robinson A, Kottschade LA, Kaur JS, McWilliams RR, Ivanov LV, Croghan GA, Markovic SN.

Front Biosci (Elite Ed). 2012 Jan 1;4:958-75.

PMID:
22201928

Supplemental Content

Loading ...
Support Center